Comparative Pharmacology
Head-to-head clinical analysis: ALPHACAINE versus ISOCAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHACAINE versus ISOCAINE HYDROCHLORIDE.
ALPHACAINE vs ISOCAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Isocaine hydrochloride is a local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and propagation of action potentials.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
1-2% solution infiltrated subcutaneously or locally, maximum dose 4.5 mg/kg (with epinephrine) or 3.0 mg/kg (without epinephrine), not to exceed 300 mg.
None Documented
None Documented
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Terminal elimination half-life is approximately 2.5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged to 6–8 hours; in severe renal impairment, half-life may extend to 4–6 hours.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Renal: Approximately 90% of the dose is excreted as metabolites (primarily conjugated with glucuronic acid) in urine. Fecal: About 10% eliminated unchanged or as metabolites in feces. Biliary excretion is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic